US2183521028
US2183521028
Corcept Therapeutics Incorporat
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 761.407.000 | 675.040.000 | 12.8% |
| Cost of Revenue | 12.977.000 | 10.882.000 | 19.3% |
| Gross Profit | 748.430.000 | 664.158.000 | 12.7% |
| 703.633.000 | 527.207.000 | 33.5% | |
| Operating Income | 44.797.000 | 136.951.000 | 67.3% |
| Pretax Income | 66.463.000 | 161.493.000 | 58.8% |
| Net Income Common Stockholders | 98.171.000 | 139.733.000 | 29.7% |
| -- | -- | -- | |
| -- | -- | -- |